This fast-paced and highly interactive livestream CaseWise™ symposium from CME Outfitters will bring real-world clinical decision-making to life. Through dynamic patient cases, learners will evaluate the latest efficacy and safety data for the IL-23p19 inhibitor class, including evidence in fistulizing and biologic-refractory disease, and integrate these findings and current guidelines into treatment selection for people with complex or difficult-to-treat IBD. Expert faculty will model the application of current IL-23p19 class evidence to real-world decisions in complex IBD cases involving prior treatment failure, comorbidities, or extraintestinal manifestations. Informed by the perspectives of expert faculty, key opinion leaders, community clinicians, and people living with IBD, learners will be better equipped to develop individualized, patient-centered treatment plans that apply shared decision-making to the goals, quality of life priorities, and access barriers of people with challenging IBD presentations.
The Satellite Symposia content and views expressed therein are those of the sponsor and not of the Crohn’s & Colitis Congress®️.